Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
50–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patients between 50 and 85 years of age with a diagnosis of probable Alzheimers Disease,
Baseline Mini-Mental State Examination (MMSE) score 10-24 inclusive,
A primary caregiver willing to accept responsibility for supervising treatment, assessing the patient's condition throughout the study, and for providing input into efficacy assessments.
For double blind only: Meet the decline criteria of functional (as assessed by the investigator) and cognitive (assessed by a 1 point reduction in Mini-Mental State Examination) score between visits or a 3 point reduction from baseline) decline at weeks 23, 36 or 48.
You may not be if
Presence of an advanced, severe, progressive, or unstable disease of any type that could interfere with efficacy and safety assessments or put the patient at particular risk,
Any medical or neurological condition other than Alzheimers Disease that could explain the patient's dementia,
A diagnosis of probable or possible vascular dementia,
A current diagnosis of unsuccessfully-treated depression, or any other mental disorder that may interfere with the evaluation of the patient's response to study medication,
A history or current diagnosis of cerebrovascular disease (e.g. stroke),
A current diagnosis of severe or unstable cardiovascular disease (e.g. unstable coronary artery disease).
Clareo Health | Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline
